

Generating Clinical Utility Data to Obtain Reimbursement

Crescendo Bioscience

Crescendo Bioscience® provides quantitative, objective molecular tests to aid rheumatologists in the effective management of patients with autoimmune and inflammatory diseases.

CHALLENGE

- Determine if knowledge and use of Vectra™ DA will be associated with higher clinical quality, less variability in clinical practice and lower costs from decreased resource utilization
- Develop clinical utility data to enable Crescendo Bioscience to obtain reimbursement for Vectra™ from CMS

SOLUTION

- QURE conducted a prospective randomized trial for Crescendo over four months in which recruited rheumatologists were asked to complete a total of 6 virtual rheumatoid arthritis CPV™ vignettes (three vignettes at baseline and another three at a second round of measurement)
- Those randomly selected for the intervention group received information about the test, as well as the Vectra DA test results if they ordered it in the CPV™

RESULTS

- Intervention group physicians had significantly higher quality scores than controls at the second measurement ($p < .05$)
- Use of Vectra improved assessment and treatment decisions by **12%** as indicated by CPV™ scores on those domains
- Two manuscripts of the results were published in the peer-reviewed literature
- Vectra™ [was approved for](#) coverage and reimbursement by CMS, meeting the criteria for analytical, clinical validity and clinical utility
- *For the full article of the published results, click [here](#).*

